byiShook Opinion
Aug 19, 2024 - 11:40
Liquidia stock crashed Monday after the FDA delayed the final approval for its drug, Yutrepia, for patients with a pair of lung diseases. The post Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38% appeared first on Investor's Business Daily.
Liquidia stock crashed Monday after the FDA delayed the final approval for its drug, Yutrepia, for patients with a pair of lung diseases.
The post Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38% appeared first on Investor's Business Daily.